ERK2

JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor, in Combination With Dabrafenib for Advanced Solid Tumors With BRAF V600E/K mutations

Retrieved on: 
Tuesday, January 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Linda, Cancer, JS, Biliary tract, Ovary, ERK, Lung, KRAS, NCI, ERK2, NRAS, ERK1, HIV disease progression rates, Trial of the century, Patient, Roswell Park Comprehensive Cancer Center, IND, MAPK, BRAF, Melanoma, Neoplasm, Pharmaceutical industry, Medical imaging

JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic solid tumors with confirmed BRAF V600E/K mutations (NCT04418167).

Key Points: 
  • JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic solid tumors with confirmed BRAF V600E/K mutations (NCT04418167).
  • JS InnoPharm holds the U.S. IND for JSI-1187, and this trial is being managed by Strategia Pharmaceuticals LLC, JS InnoPharm’s clinical development partner in the United States.
  • The JSI-1187 monotherapy dose escalation phase of this study was initiated in 2020 for the treatment of patients with relapsed or refractory, locally advanced or metastatic solid tumors with MAPK pathway mutations, including hyperactivating mutations or gene fusions.
  • Therefore, a combination of ERK inhibition with JSI-1187 and dabrafenib may provide a targeted approach to delay or overcome resistance, as ERK is the most distal kinase of the MAPK signaling pathway.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, MAPK, Encorafenib, SAN, NSCLC, RAF, RTK, Large-cell lung carcinoma, Partnership, Pfizer, RAS, Patient, Progression-free survival, ERK1, BRAF, SHP2, Investment, Security (finance), GI, Annual report, Cancer, Pierre Fabre, Cetuximab, Research, ERK, ERK2, Clinical trial, CRC, Form 10-K, FDA, Pharmaceutical industry

SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pierre Fabre for the BRAF inhibitor encorafenib (BRAFTOVI®) within key international territories.

Key Points: 
  • Erasca will sponsor the trial, and Pierre Fabre will supply encorafenib in the Pierre Fabre territories which include Europe and Asia Pacific (excluding Japan and South Korea).
  • This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets.
  • Encorafenib in combination with cetuximab was approved by the FDA in April 2020 for previously treated patients with BRAF V600E-mutant mCRC.
  • HERKULES-3 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with GI cancers.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

Retrieved on: 
Thursday, October 20, 2022
SAN, U.S. Securities and Exchange Commission, Pancreatic cancer, PDAC, SEC, PFE, NRAS, NYSE, Patient, ERK2, Research, Annual report, RAF, Security (finance), CRC, Investment, ERK1, RAS, GI, KRAS, Cancer, Private Securities Litigation Reform Act, Form 10-K, RTK, Mutation, ERK, NSCLC, Industry, CEO, SHP2, GLOBE, Clinical trial, Cell cycle, COVID-19, Large-cell lung carcinoma, Pharmaceutical industry, Pfizer

SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pfizer Inc. (NYSE: PFE) for the CDK4/6 inhibitor palbociclib (IBRANCE®).

Key Points: 
  • The combination is currently being investigated as part of the ongoing Phase 1b/2 HERKULES-3 master protocol clinical trial in patients with gastrointestinal (GI) malignancies.
  • Erasca is sponsoring the study, and Pfizer is supplying palbociclib at no cost.
  • HERKULES-2 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with non-small cell lung cancer (NSCLC).
  • HERKULES-3 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with GI cancers.

BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine

Retrieved on: 
Monday, September 12, 2022
Institute, Stowers Institute for Medical Research, MAPK, Autophagy, Phase, American Century, Neoplasm, Century, University, Investment, BRAF, Hydroxychloroquine, ERK2, Survival, ERK, Patient, Clinical trial, BVD, Huntsman Cancer Institute, Medical research, Tumor microenvironment, HCQ, ERK1, American Century Companies, Mutation, Pharmaceutical industry

KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).

Key Points: 
  • KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).
  • Ulixertinib is a first-in-class and best-in-class ERK inhibitor, with this clinical trial focusing on patients with advanced gastrointestinal malignancies and mutations in the MAPK pathway.
  • Previous efforts have also established a recommended phase 2 dose in combination with palbociclib, with additional combination efforts ongoing.
  • About BioMed Valley Discoveries (BVD): BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas.

Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials

Retrieved on: 
Wednesday, September 7, 2022
Security (finance), COVID-19, CEO, Cancer, Safety, ERK1, Research, HPV, Form 10-K, Large-cell lung carcinoma, Pancreatic cancer, SAN, RAF, Head, RTK, SEC, Gastrointestinal cancer, U.S. Securities and Exchange Commission, BRAF, KRAS, GLOBE, Patient, SHP2, NSCLC, RAS, Receptor tyrosine kinase, CRC, Annual report, ERK, Private Securities Litigation Reform Act, Industry, ERK2, HNSCC, Colorectal cancer, Pharmaceutical industry

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.

Key Points: 
  • We anticipate initiating a dose escalation trial for ERAS-007 in combination with ERAS-601 in the first half of 2023.
  • HERKULES-3 is a Phase 1b/2 master protocol for ERAS-007 in combination with various agents in patients with gastrointestinal cancers.
  • HERKULES-1 is a Phase 1b/2 clinical trial that will include evaluation of ERAS-601 in combination with ERAS-007 in advanced solid tumors.
  • HERKULES-2 is a Phase 1b/2 master protocol that includes evaluation of ERAS-601 in combination with various agents in patients with NSCLC.

Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors

Retrieved on: 
Wednesday, August 24, 2022
KOL, Security (finance), COVID-19, Jesse, Thomas Jefferson University Hospital, Cancer, ERK1, Research, MAPK, Form 10-K, MD Anderson Cancer Center, Therapy, Albert Einstein College of Medicine, RAF, RTK, Department, GI, SEC, Investment, U.S. Securities and Exchange Commission, GLOBE, Yale University, SHP2, NSCLC, RAS, Receptor tyrosine kinase, CRC, Clinical trial, Annual report, ERK, Industry, Drug development, ERK2, HNSCC, Private Securities Litigation Reform Act, Oncology, Patient, Pharmaceutical industry, Online shopping

SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it will host a research and development day, with a focus on the company’s ERAS-007 ERK1/2 inhibitor and ERAS-601 SHP2 inhibitor in advanced solid tumors, on Wednesday, September 7, 2022, at 4:30 PM Eastern Time.

Key Points: 
  • Erasca, who will present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERAS-007 and ERAS-601, for the treatment of advanced solid tumors with RAS/MAPK pathway alterations.
  • David S. Hong, M.D., serves as deputy chair in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas.
  • Dr. Hong earned his medical degree from Albert Einstein College of Medicine in 1999, following his undergraduate studies in oncology at Yale University.
  • FLAGSHP-1 is a Phase 1/1b dose escalation trial evaluating ERAS-601 as a monotherapy in advanced solid tumors and in combination in triple wildtype CRC and HPV-negative advanced HNSCC.

Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers

Retrieved on: 
Tuesday, August 23, 2022
National, University, COVID-19, Security (finance), National Cancer Institute, CEO, U.S. Securities and Exchange Commission, Cancer, ERK1, Research, HPV, Form 10-K, MAPK, Large-cell lung carcinoma, Therapy, Pancreatic cancer, SAN, News, RAF, RTK, P30, MD Anderson Cancer Center, Monroe Dunaway Anderson, GI, Treatment of lung cancer, SEC, Education, Investment, Hospital, Cetuximab, BRAF, KRAS, MD, GLOBE, Anderson, SHP2, RAS, Receptor tyrosine kinase, NCI, CRC, Clinical trial, Annual report, ERK, Private Securities Litigation Reform Act, Industry, ERK2, HNSCC, U.S. News & World Report, Patient, Pharmaceutical industry, NSCLC

SAN DIEGO and HOUSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, and The University of Texas MD Anderson Cancer Center (MD Anderson), today announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway as either single-agent or combination therapies.

Key Points: 
  • Our strategic collaboration with MD Anderson broadens the evaluation of ERAS-007 and ERAS-601 and explores additional therapeutic opportunities across our pipeline, said Jonathan E. Lim, M.D., Erascas chairman, CEO, and co-founder.
  • The RAS/MAPK pathway is one of cancers most frequently altered pathways, affecting more than 5 million new patients with cancer annually worldwide.
  • The alliance will build on Erascas existing collaborations with MD Anderson investigators Scott Kopetz, M.D., Ph.D. , professor of Gastrointestinal Medical Oncology , and David S. Hong, M.D.
  • MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Retrieved on: 
Thursday, June 2, 2022
Colorectal cancer, Large-cell lung carcinoma, Research, Associate, Harvard Medical School, MAPK, CEO, SHP2, Stand Up to Cancer, Security (finance), Gastrointestinal cancer, U.S. Securities and Exchange Commission, SU2C, Investment, ERK, Drug resistance, Massachusetts General Hospital, DRS, Patient, GLOBE, Private Securities Litigation Reform Act, RAS, RAF, CRC, COVID-19, SAN, SEC, Industry, ERK2, MEK, RTK, Hospital, ERK1, University, KRAS, NSCLC, Corcoran, MD Anderson Cancer Center, Lymphatic system, Cancer, Safety, Pharmaceutical industry, Medicine

Additionally, it may provide proof-of-concept data supporting the addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance with KRAS G12C inhibitors.

Key Points: 
  • Additionally, it may provide proof-of-concept data supporting the addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance with KRAS G12C inhibitors.
  • We look forward to potentially partnering with the team to explore the therapeutic potential of this combination.
  • A Phase 1b clinical proof-of-concept trial will evaluate ERAS-007 in combination with a KRAS G12C inhibitor in patients with NSCLC and CRC harboring a KRAS G12C mutation.
  • HERKULES-3 is a Phase 1b/2 clinical trial for ERAS-007 in combination with various agents in patients with gastrointestinal cancers.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination

Retrieved on: 
Thursday, March 10, 2022
Industry, Clinical trial, Lymphatic system, Cetuximab, Large-cell lung carcinoma, Private Securities Litigation Reform Act, Company, Research, SHP2, U.S. Securities and Exchange Commission, MEK, MAPK, Cancer, Mutation, Encorafenib, Investment, Gastrointestinal cancer, Eli Lilly and Company, RAF, Pfizer, ERK, RTK, ERK2, GLOBE, Patient, RAS, Security (finance), ERK1, COVID-19, BRAF, SEC, CEO, SAN, Eli Lilly, CRC, Pharmaceutical industry, Lilly

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company for Lilly’s anti-EGFR antibody cetuximab (ERBITUX®).

Key Points: 
  • Erasca will sponsor the study, and Lilly will supply cetuximab at no cost.
  • HERKULES-2 is a Phase 1b/2 clinical trial for ERAS-007 in combination with various agents in patients with non-small cell lung cancer.
  • HERKULES-3 is a Phase 1b/2 clinical trial for ERAS-007 in combination with various agents in patients with gastrointestinal cancers.
  • ERBITUX is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Retrieved on: 
Wednesday, September 22, 2021
ERK, SHP2, Clinical trial, Neoplasm, CRC, MD Anderson Cancer Center, Security (finance), RAF, Massachusetts, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Cancer, MAPK, BRAF, Patient, RAS, AACR, ERK2, Cetuximab, NSCLC, Industry, CEO, MEK, NRAS, Large-cell lung carcinoma, SAN, GI, Encorafenib, COVID-19, Lymphatic system, Research, RTK, Safety, KRAS, ERK1, Investment, Mutation, SEC, GLOBE, Pharmaceutical industry

We have developed HERKULES-3, our GI master protocol, to evaluate ERAS-007 in rational combinations to assess the possibility of reducing susceptibility to resistance and increasing durability of treatment.

Key Points: 
  • We have developed HERKULES-3, our GI master protocol, to evaluate ERAS-007 in rational combinations to assess the possibility of reducing susceptibility to resistance and increasing durability of treatment.
  • Another 45-50% of CRC patients have tumors that harbor KRAS or NRAS mutations, for which there is currently no approved targeted therapeutic option.
  • HERKULES-3 will examine the safety, tolerability, and preliminary efficacy of ERAS-007 in combination with other cancer therapies in study participants with GI malignancies.
  • Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.